skip to Main Content

FDA Panel Backs Maintenance Olaparib for Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 in favor of olaparib (Lynparza) tablets for an indication as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

The FDA scheduled an Oncologic Drugs Advisory Committee hearing to discuss a supplemental new drug application (sNDA) for olaparib in this setting, which was based on results from the phase III POLO trial.  Read more . . . 


Back To Top